The Peptide Pipeline Is Exploding: Over 150 Compounds in Active Clinical Trials in 2026
The global peptide therapeutics pipeline has reached an unprecedented scale in 2026, with more than 150 compounds currently in active clinical trials and AI tools compressing discovery timelines from years to months. The pace of FDA peptide drug approvals over the last eight years alone has outstripped the entire two decades prior.
Source: Peptide Protocol Wiki / Intelligent Living 2026
Peptide-Drug Conjugates: Six in Phase III Trials as Market Eyes $1.5 Billion Opportunity
A new 2026 market landscape report projects the global peptide-drug conjugate (PDC) sector will reach $1.5 billion by 2031, with six candidates currently in Phase III trials and approximately 96 more in active development — primarily targeting oncology applications.
Source: GlobeNewswire
Peptide Market Expansion: Emerging Trends and Forecasts for 2026
The peptide therapeutics market is expected to witness unprecedented growth driven by innovations in drug development and rising demand for targeted therapies.
Source: ThePBrief Research
Market Trends: Peptide Therapeutics Surge in Popularity Among Investors
New market analysis shows that investments in peptide therapeutics are skyrocketing, with a projected compound annual growth rate of 15% over the next five years.
Source: ThePBrief Research
The Peptide Market Launched into a New Era: Industry Dynamics in 2026
The peptide market is witnessing exponential growth, driven by innovative therapies and increased investments in biopharmaceutical research, signaling a prosperous future.
Source: ThePBrief Research
Peptide Market Growth Accelerating: 2026 Industry Report Highlights
A recent report reveals that the global peptide market is expected to grow exponentially, fueled by increased research, advancements in drug development, and rising demand for peptide therapeutics.
Source: ThePBrief Research
Tirzepatide Gains Monthly Dosing Option as Competition Intensifies in Obesity Market
The FDA has approved a new monthly KwikPen delivery format for tirzepatide, reducing injection frequency and improving convenience just as rival obesity drugs approach regulatory review.
Source: AJMC � American Journal of Managed Care
Emerging Market for Peptide Therapies: Investment and Innovation on the Rise
The peptide therapeutics market is poised for substantial growth, spurred by increased investment and innovation, particularly in metabolic disorders and oncology.
Source: ThePBrief Research
Retatrutide Delivers 28.7% Weight Loss in Phase 3 � The Most Potent Obesity Peptide Yet
Eli Lilly's retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, achieved 28.7% average body weight loss at 68 weeks in its TRIUMPH-4 Phase 3 trial, outperforming all currently approved obesity drugs.
Source: Eli Lilly Investor Relations
Market Trends: The Rising Demand for Peptide Therapeutics in Cancer Treatment
The market for peptide therapeutics in oncology is witnessing substantial growth, driven by advancements in precision medicine and novel peptide designs.
Source: ThePBrief Research
Global Peptide Synthesis Market Hits $1.9 Billion as Demand Surges
A new industry report shows the global research peptide market has reached $1.9 billion in 2026, driven by therapeutic demand and projected to hit $2.59 billion by 2031.
Source: GlobeNewsWire
FDA Approves Foundayo (Orforglipron) — First Daily Oral GLP-1 Pill for Weight Loss
Eli Lilly's Foundayo becomes the first once-daily oral GLP-1 receptor agonist approved by the FDA, eliminating the need for injections in obesity treatment.
Source: Medical News Today
Daily Briefing
Get the latest peptide research delivered to your inbox every morning.
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.